Research programme: kamuvudines - Inflammasome Therapeutics
Latest Information Update: 02 May 2024
At a glance
- Originator Inflammasome Therapeutics
- Class Eye disorder therapies
- Mechanism of Action Inflammasome inhibitors; NLRP3 protein inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Type 2 diabetes mellitus
Most Recent Events
- 29 Apr 2024 Updated pharmacodynamics data from a preclinical trial Age-related macular degeneration released by Inflammasome Therapeutics
- 06 Dec 2021 Inflammasome Therapeutics plans a clinical trial in 2022
- 05 Feb 2021 Inflammasome Therapeutics has pending patents for kamuvudines in Australia, Europe, Canada